Fennec Pharmaceuticals Inc. FENC 深 沪
等待开盘 09-22 09:30:00 美东时间
10.91
+0.290
+2.73%
华盛通- 最 高10.94
- 今 开10.63
- 成交量 13.29万股
- 最 低 10.43
- 昨 收 10.62
- 总市值 3.83亿
- 52周最高 13.25
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 5.65
- 委 比 -78.54%
- 总股本 3506.72万
- 历史最高 14.986
- 量 比 0.77
- 振 幅 4.80%
- 历史最低 3.255
- 每 手 1
- 风险率 1.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Fennec Pharmaceuticals announced positive results from the STS-J01 clinical trial evaluating PEDMARK® for reducing cisplatin-induced ototoxicity in pediatric and AYA patients in Japan. The study enrolled 33 patients, with 24.0% experiencing ASHA-defined hearing loss, significantly below the historical benchmark of 56.4% (P=0.001). No Grade 3 or 4 hearing loss was observed, and objective tumor responses were seen in 95.8% of evaluable patients. Pr...
09-17 11:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
09-09 19:18
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
08-13 00:04
Fennec Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Fennec Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
08-11 22:51
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $17.874 mi...
08-11 19:03
Today’s Market Recap: S&P, Dow Snap Winning Streak，Nvidia Drops 3%, Intel Plunges 4%, Coherent Crashes 10%
Tradingkey - On August 10, Eastern Time, tech stocks weighed on U.S. markets, causing both the S&P 500 and the Dow Jones Industrial Average to decline
08-11 00:50
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Fennec Pharmaceuticals Inc. will release its Q2 2026 financial results on August 11, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 a.m. Eastern Time. Details and registration links are available on the company’s website. Fennec, focused on reducing cisplatin-induced ototoxicity in cancer patients, commercializes PEDMARK®/PEDMARQSI®, approved in the U.S., Europe, and the U.K. The company has an exclusiv...
08-05 11:01
